Log Out

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Down 15.5%

Defense World · Sep 15, 2022 06:12

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating)'s stock price traded down 15.5% during trading on Tuesday . The stock traded as low as $26.24 and last traded at $26.34. 13,199 shares were traded during mid-day trading, a decline of 98% from the average session volume of 559,124 shares. The stock had previously closed at $31.18.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Cowen assumed coverage on Zentalis Pharmaceuticals in a research note on Tuesday, July 12th. They issued an "outperform" rating on the stock. SVB Leerink cut their price target on Zentalis Pharmaceuticals from $67.00 to $42.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 10th. Morgan Stanley cut their price objective on Zentalis Pharmaceuticals from $95.00 to $60.00 and set an "overweight" rating on the stock in a research note on Thursday, August 11th. HC Wainwright cut their price objective on Zentalis Pharmaceuticals from $120.00 to $55.00 and set a "buy" rating on the stock in a research note on Wednesday, August 10th. Finally, Cowen started coverage on Zentalis Pharmaceuticals in a research note on Tuesday, July 12th. They set an "outperform" rating on the stock. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $61.38.

Get Zentalis Pharmaceuticals alerts:

Zentalis Pharmaceuticals Trading Down 6.5 %

The company has a fifty day moving average price of $28.44 and a 200 day moving average price of $30.79.

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) last posted its earnings results on Tuesday, August 9th. The company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.21) by ($0.13). On average, sell-side analysts predict that Zentalis Pharmaceuticals, Inc. will post -4.78 EPS for the current fiscal year.

Insider Activity

In related news, COO Kevin D. Bunker sold 25,000 shares of the stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $30.07, for a total value of $751,750.00. Following the completion of the transaction, the chief operating officer now directly owns 110,000 shares of the company's stock, valued at approximately $3,307,700. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, COO Kevin D. Bunker sold 25,000 shares of the stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $30.07, for a total value of $751,750.00. Following the completion of the transaction, the chief operating officer now directly owns 110,000 shares of the company's stock, valued at approximately $3,307,700. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Kevin D. Bunker sold 1,710 shares of the stock in a transaction on Wednesday, July 13th. The shares were sold at an average price of $30.02, for a total value of $51,334.20. Following the transaction, the chief operating officer now directly owns 108,290 shares of the company's stock, valued at $3,250,865.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 31,710 shares of company stock valued at $953,084. 19.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Captrust Financial Advisors lifted its position in shares of Zentalis Pharmaceuticals by 15,160.0% during the 1st quarter. Captrust Financial Advisors now owns 763 shares of the company's stock valued at $35,000 after acquiring an additional 758 shares during the last quarter. Assetmark Inc. lifted its position in shares of Zentalis Pharmaceuticals by 337.3% during the 2nd quarter. Assetmark Inc. now owns 1,054 shares of the company's stock valued at $30,000 after acquiring an additional 813 shares during the last quarter. Advisor Group Holdings Inc. lifted its position in shares of Zentalis Pharmaceuticals by 1,082.5% during the 4th quarter. Advisor Group Holdings Inc. now owns 1,218 shares of the company's stock valued at $102,000 after acquiring an additional 1,115 shares during the last quarter. US Bancorp DE lifted its position in shares of Zentalis Pharmaceuticals by 378.9% during the 1st quarter. US Bancorp DE now owns 1,451 shares of the company's stock valued at $67,000 after acquiring an additional 1,148 shares during the last quarter. Finally, Point72 Hong Kong Ltd acquired a new stake in shares of Zentalis Pharmaceuticals during the 1st quarter valued at $72,000.

About Zentalis Pharmaceuticals

(Get Rating)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.